title: Proliferating Cell Nuclear Antigen Has an Association with Prognosis and Risks Factors of Cancer Patients: a Systematic Review.
abstract: Proliferating cell nuclear antigen (PCNA) is reported as a famous marker in various tumors. A couple of articles have been published about the clinical function of PCNA on cancer progression; however, these results are conflicting in some degree. Thus, it is crucial to perform a systematic review and meta-analysis to identify their real actions. Here, we took cervical cancer and glioma as example and then pooled hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (95 % CIs). In the present study, the PCNA expression in cervical cancer and gliomas patients was both correlated with 5-year-overall survival (OS) (HR = 4.41, 95 % CI 2.71-7.17, p = 0.000; HR = 4.40, 95 % CI 3.00-6.47, p = 0.000; respectively). In addition, a fixed effect model revealed a significant association between PCNA and FIGO stage (OR = 4.48, 95 % CI 3.48-5.77, p = 0.000) or WHO grade (OR = 5.64, 95 % CI 4.15-7.68, p = 0.000), rather than age (OR = 1.01, 95 % CI 0.71-1.43, p = 0.957; OR = 1.00, 95 % CI 0.80-1.24, p = 0.989; respectively). No heterogeneity was observed across all studies. According to funnel plot, no publication bias was reported. In conclusion, our systematic review suggests that PCNA expression is significantly associated with poor 5-year survival, advanced stage or higher WHO grade, which might be suggested as a useful prognostic and diagnostic biomarker, or an effective therapy target in cervical cancer, gliomas, or even more cancers.
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Qiongying
authors.initials: Q
authors.lastname: Lv
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Zhang
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Yuexiong
authors.initials: Y
authors.lastname: Yi
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Huang
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China.
authors.forename: Yijun
authors.initials: Y
authors.lastname: Wang
authors.affiliation: First Department of Gynaecology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, China. zhangweiwuhan163@163.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000378:metabolism*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*; D017594:Publication Bias; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D018809:Proliferating Cell Nuclear Antigen
keywords: Diagnosis; PCNA; Prognosis; Systematic review